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A B S T R A C T
Retroperitoneal liposarcomas are rare tumours that carry a poorer prognosis than their extremity counterparts.
Within their subtypes – well differentiated (WDL), dedifferentiated (DDL), myxoid (MLS) and pleomorphic (PLS)
- they exhibit a diverse genomic landscape. With recent advances in next generation sequencing, the number of
studies exploring this have greatly increased. The recent literature has deepened our understanding of the
hallmark MDM2/CDK4 amplification in WDL/DDL and addressed concerns about toxicity and resistance when
targeting this. The FUS-DDIT3 fusion gene remains the primary focus of interest in MLS with additional potential
targets described. Whole genome sequencing has driven identification of novel genes and pathways implicated in
WDL/DDL outside of the classic 12q13-15 amplicon. Due to their rarity; anatomical location and histologic
subtype are infrequently mentioned when reporting the results of these studies. Reports can include non-adi-
pogenic or extremity tumours, making it difficult to draw specific retroperitoneal conclusions. This narrative
review aims to provide a summary of retroperitoneal liposarcoma genomics and the implications for therapeutic
targeting.
Introduction
Retroperitoneal liposarcomas (RPL) are rare tumours that are
challenging to manage surgically, and generally respond poorly to
chemotherapy. They possess high local recurrence rates and in certain
subtypes can metastasise. The retroperitoneum represents the second
most common site of origin of these tumours after the extremities.
There is general consensus in the sarcoma community that surgery to
remove RPL with clear margins is the most beneficial intervention to
improve recurrence free survival, and possibly overall survival. Early
data from the largest trial of neoadjuvant radiotherapy in retro-
peritoneal sarcomas has alluded to a potential subgroup benefit in pa-
tients with liposarcoma [1]. However, even with successful surgery and
appropriately utilised radiotherapy, long-term control rates still require
a significant improvement and for this a deeper understanding of the
genomic aberrations that underpin the disease are required.
This review explores the current understanding of the genomic
landscape in retroperitoneal liposarcoma and the consequences on
therapeutic strategy. The anatomical focus on the retroperitoneum,
rather than the extremity is undertaken for several reasons. Firstly, a
summary of specific retroperitoneal liposarcoma genomics is lacking in
the literature. This would be useful to clinicians and scientists alike,
dealing with this specific disease in the era of personalised medicine.
Secondly, it is well established that variations in the tumour micro-
environment can determine response to therapy. Lastly, RPL carries a
poorer prognosis than extremity LS, has a distinct natural history and is
managed differently.
Methods
Search strategy
A literature search was conducted using the Embase, MEDLINE,
PubMed and Cochrane Library databases. The following keywords were
used to perform flexible searches within these databases:
‘Retroperitoneal’ AND ‘sarcoma’, ‘liposarcoma’, ‘genomics’, ‘genetics’,
‘mutation’, and ‘genomic therapy.’ Only papers published in English
were included.
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Structure
An overview of the genomic aberrations and genome targeted
therapies is presented for the four types of liposarcoma. As well-dif-
ferentiated (WDL) and dedifferentiated liposarcoma (DDL) account for
>90% of retroperitoneal liposarcomas these are the main focus of the
article. Some consideration has also been given to the two rarer sub-
types, myxoid (MLS) and pleomorphic (PLS) liposarcoma. Efforts are
made to report retroperitoneal findings of studies where this data is
available. Nevertheless, some data will be from published literature that
does not state the anatomical site and some time is given to discussing
the genomic differences, if any, between retroperitoneal and extremity
liposarcoma. As a consequence of the high-quality outputs of next
generation sequencing, genes and related pathways that are con-
sistently found in well conducted research are prioritised above those
with minor relevance or in small datasets.
Well differentiated liposarcoma (WDL)
Well differentiated liposarcoma (WDL) is a low-grade tumour,
composed of proliferating mature adipocytes and accounts for 40–45%
of all liposarcomas [2]. In the retroperitoneum it is termed well-dif-
ferentiated liposarcoma and accounts for 25% of WDL, the remaining
75% being located in the extremities. In the extremity it is termed
atypical lipomatous tumour or ALT. Retroperitoneal tumours are fre-
quently > 30 cms in size at diagnosis. They do not metastasise, but
have a high propensity for local recurrence with rates of up to 43% at
8 years when not given radiotherapy [3]. Furthermore, 20% of WDL
will dedifferentiate to a higher grade tumour, on average at seven to
eight years [4].
The cytogenetic signature of WDL is supernumerary ring chromo-
somes which contain amplified sequences from the long arm of chro-
mosome 12 (12q13-15). The mutational mechanisms underlying the
original amplification are an important area of liposarcoma genomics.
Marino-Enriquez et al. believe that an early initiation event – chro-
mothripsis – results in massive fragmentation and rearrangement of the
chromosome [5]. An amplification phase follows in which repetitive
break-fusion bridge cycles allow incorporation of additional chromo-
somal regions to the ring neochromosomes and concludes with neo-
chromosome stabilisation. This ‘initiation event’ could be a funda-
mentally random event which then becomes fixed through natural
selection in a precursor cell [6], or a specific mechanism yet to be
discovered.
This amplified region of chromosome 12 harbours multiple im-
portant genes, which are also implicated in other cancers. The most
compelling evidence to date demonstrates an oncogenic role in WDL for
Mouse double minute 2 (MDM2), Cyclin-dependent kinase 4 (CDK4)
and High mobility group protein AT-hook 2 (HMGA2). In general am-
plification of the region results in increased cell proliferation and de-
creased apoptosis [66]. Outside of this amplicon, additional genes
PPAR- and RET are implicated as well as the FGFR pathway.
MDM2
MDM2 is the most studied of all genomic aberrations in WDLS. Its
amplification has been considered to represent one of the earliest events
in the formation of WDL and DDL [2]. Although, as it potentially re-
quires extrachromosomal material to be formed, it is perhaps not the
primary event. MDM2 encodes a negative regulator of the tumour
suppressor p53, blocking it’s transcription and targeting p53 for pro-
teasomal degradation [7]. Low levels of p53 cause an abrogation of the
tumour suppressive p53 pathway and allow cells to progress through
the cell cycle under conditions that could generate or perpetuate DNA
damage, thus initiating tumourigenesis [8].
MDM2 amplification is seen in 7% of human cancers and a third of
all sarcomas, whereas rates are far higher in WDL and DDL [9]. MDM2
amplification is observed in both RPL and extremity ALT, but not
usually seen in benign adipose tissue. Somaiah et al. performed exome
sequencing on 17 patients with retroperitoneal WDL and DDL. MDM2
and CDK4 amplification were the only two overlapping gene amplifi-
cations universally identified in all the samples [10].
There is good evidence from preclinical studies that p-53 wildtype,
MDM2-amplified tumours respond to p53 activation and apoptosis with
MDM2 antagonist treatment [11]. As liposarcomas harbour very few
p53 mutations and are generally MDM2 amplified, MDM2 antagonists
have been tested in several phase one clinical studies since 2017.
(Fig. 1)
Only two studies have specifically reported onMDM2 antagonists in
patients with WDL. Ray-Coquard et al. in a chemotherapy naïve cohort
of predominantly RPL, showed no progression in 9/10 WDL, but only
one partial response [12]. Wagner et al. in 9 patients with advanced
WDL found 4 patients had prolonged stable disease with one prolonged
partial response [13] . Both studies reported at least one adverse effect
in each patient, with Wagner et al. reporting 1/3 experiencing serious
adverse effects.
The putative benefits of MDM2 inhibition in liposarcoma need ba-
lanced against these adverse effects, which are likely exacerbated when
combined with standard chemotherapy or other targeted agents.
Furthermore, emerging evidence suggests resistance to MDM2 inhibi-
tion occurs through p53 mutation [14]. Therefore, more work is needed
to increase drug specificity and avoid early resistance patterns.
CDK4
CDK4 is amplified in over 90% of retroperitoneal WDL/DDL making
it the second most commonly amplified gene in liposarcoma [15]. CDK4
encodes a protein which phosphorylates retinoblastoma protein (pRB),
dissociating it from the pRB-E2F complex. Dissociated E2F subse-
quently binds to DNA, upregulating the transcription of genes required
for G1-S transition [16]. In simple terms, amplification of this gene
leads to cell cycle progression.
Even though situated very closely on chromosome 12, the rear-
ranged chromosome in liposarcoma is discontinuous, and CDK4 and
MDM2 are likely from distinct amplicons [17]. Co-amplification of
Fig. 1. MDM2 amplification by Fluorescence In Situ Hybridisation (FISH).
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MDM2 and CDK4 is thought to be the main driving factor in lipo-
sarcomagenesis, leading to p53 inactivation and uncontrolled cell cycle
progression.
Lee et al. performed real-time PCR on 48 patients who had under-
gone compete resection of an intraabdominal liposarcoma (96% retro-
peritoneal, 31 WDL/17DD) [15]. WDL that developed a local recur-
rence had significantly higher levels of CDK4 amplification
(P = 0.041). High levels of CDK4 amplification was associated with
poorer RFS compared to low CDK4 amplification in both univariate and
multivariate analysis.
These findings paved the way for pre-clinical research with CDK4
antagonists. Helias-Rodzewicz et al. treated liposarcoma cell lines with
a CDK4 inhibitor NSC625987 and observed a dramatic increase in
adipocytic differentiation in cells with eliminated copies of CDK4 [18].
Perez et al. induced senescence in both liposarcoma cell lines and mice
xenografts using palbociclib, a selective CDK4/6 inhibitor [19].
Palbociclib is used to treat ER-positive/EGFR2-negative breast
cancer and represents the first FDA approved drug in its class [20]. Four
trials using CD4 antagonists have reported in retroperitoneal lipo-
sarcoma, two using palbociclib, one using ribociclib and the last a pan-
CDK inhibitor – flavopiridol – in combination with doxorubicin
[21–24]. The largest of these to report included 15 patients with ret-
roperitoneal WDL [22]. The 12-week progression-free survival (PFS)
rate was 57.2% with one complete response. The most common adverse
events were haematological.
HMGA2
HMGA2 encodes for a protein that alters chromatin structure and in
sarcomas (liposarcomas, uterine leiomyosarcomas and salivary gland
pleomorphic adenomas) is found to be rearranged, amplified and
overexpressed [25]. Interestingly HMGA2 is found to be rearranged in
up to 70% of benign lipomata, resulting in a truncated protein, and is
implicated in their development.
In a series of 38 liposarcomas (7/38 retroperitoneal WDL), Italiano
et al used FISH and RT-PCR, to detail the amplification status and ex-
pression levels of the 12q13-15 amplicon. HMGA2 was amplified and
rearranged in every sample, at a rate similar to that of MDM2 [17].
More recently, a separate group used similar techniques showing am-
plification of the proximal parts of HMGA2 (5′-untranslated region
(UTR) and exons 1–3) was associated with WDL and a good prognosis,
whereas CDK4 and JUN amplifications were associated with DDL and a
poorer prognosis [26].
Xi et al demonstrated that HMGA2 is required for C/EBPβ-mediated
expression of PPARγ – the master adipogenesis regulator, promoting
adipogenic differentiation. When HMGA2 was knocked down, it im-
paired adipocyte growth and when overexpressed promoted the for-
mation of mature adipocytes [27]. Furthermore, Arlotta et al. hy-
pothesised that the HMGA2 protein specifically promoted the growth of
adipocytes. This was confirmed by the very low-fat phenotype of a
HMGA2 knock-out mouse. In transgenic mice with a truncated HMGA2
there was a high incidence of lipomatosis further linking HMGA2 to a
role in adipogenesis [28].
Narita et al demonstrated that HMGA2 proteins cooperate with the
p16 tumour suppressor to promote cellular senescence, but this anti-
proliferative activity is negated by co-expression of MDM2 and CDK4
[29]. This led others to believe that HMGA2 alone will only lead to
benign lipomata, but in combination with MDM2/CDK4 amplification,
a malignant phenotype would be induced [17].
FRS2
There has been a recent drive to identify other novel genes present
on the 12q13-15 amplicon of which Fibroblast growth factor receptor
substrate 2 (FRS2) is one. FRS2 codes for a signal transducing protein
that links receptor tyrosine kinases (RTKs) to downstream signalling
pathways, such as MAPK/ERK and PI3K/AKT/mTOR [30].
In one study, FRS2 was amplified in all 57 liposarcomas and mRNA
transcriptional upregulation documented in 19 WDL samples, but not in
lipomata or normal fat. Jing et al more recently evaluated the frequency
of FRS2 amplification and its relationship with clinical features. In their
series 92.1% of WDL were FRS2 amplified, and retroperitoneal tumours
were found to have a higher FRS2/CEP12 ratio than those in the ex-
tremity [31].
Importantly, Zhang et al. have shown that the FGFR selective in-
hibitor NVP-BGJ-398 inhibited the growth of high grade liposarcoma
cell lines with concomitant suppression of FGFR signal transduction
[32]. This pathway serves as an additional potential therapeutic target.
There are several other genes studied to varying degrees present on
the 12q13-15 amplicon, such as SAS, GLI and HOXC [33]. Others such
as YEATS4 and TSPAN 31 are more relevant to DDL and will be covered
in that section.
Outside of the 12q13-15 amplicon
As sequencing technologies have improved, a deeper interrogation
of the genome has become possible. Egan et al. were the first group to
perform whole genome sequencing on a WDL, in order to search for
therapeutic targets outside of the 12q13-15 amplicon. They found 7
damaging single nucleotide variants, amplification across multiple
chromosomes and 11 gene fusions [34]. Of note, they identified a po-
tential gene fusion via whole genome sequencing (WGS) in amplified
Discoidin domain-containing receptor 2 (DDR2), a gene involved in
multiple cellular processes and present on 1q23.3. Importantly, the
kinase domain was predicted to remain intact, which is of clinical re-
levance as DDR2 activity can be curtailed by kinase inhibitors such as
imatinib, nilotinib and dasatanib.
Dedifferentiated liposarcoma (DDL)
DDL is a high grade, more aggressive, typically non-lipogenic sar-
coma with the ability to metastasise [35]. It can either arise de novo, as
a recurrence of WDL or juxtaposed to WDL. Dedifferentiation is the
term used to describe this morphological progression. In an inverse
relationship to WDL, 75% of DDL are of retroperitoneal origin, with
25% in the extremity [36]. The molecular basis of dedifferentiation is
poorly understood but of great interest in sarcoma genomics as this
carries a far poorer survival. This section starts with proposed genomic
drivers of dedifferentiation, addresses the commonly amplified genes
on 12q13-15 and finishes with genomic aberrations unique to DDL.
Genomic drivers of dedifferentiation
The genomic changes associated with progression from WDL to DDL
are complex and poorly understood. Both subtypes harbour the neo-
chromosomes and oncogenes previously explored. Nevertheless, DDL
tumours must possess additional mechanisms to become high grade,
more cellular and aggressive; not resembling their original histological
appearance. In general, DDL exhibit more complex chromosomal
aberrations [37].
A major element of dedifferentiation is loss or downregulation of
adipogenesis. This downregulation results in a non-lipogenic tumour
mass which can be difficult to distinguish histologically. Genes involved
in adipocyte metabolism such as LIPE, PLIN and PLIN2 are amongst
those uniquely absent in DDL, suggesting a loss of ability to act like fat
in these tumour cells [38,39]. Additionally, DDL tends to have a more
rearranged genome, especially the 12q13-15 amplicon which contains
genes which control adipocyte differentiation such as CPM and HMGA2.
R. Tyler, et al. Cancer Treatment Reviews 86 (2020) 102013
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Beird et al. compared the genomic landscape of synchronous WDL
and DDL components of 17 tumours (15 retroperitoneal). There were
three main findings: firstly, a low somatic mutational burden across
both tumour types. Secondly, the presence of shared somatic mutations,
albeit in low number. Finally, they identified a significantly larger
number of gene fusions and copy number alterations in DDL when
compared to WDL [40]. The higher copy number alterations and gene
fusions in DDL were attributed to the result of increased break-fusion
bridge cycles. The authors also suggested that the low number of similar
somatic mutations meant tumours derived from a common ancestral
clone but diverged early in their development. They hypothesised that
the capacity to dedifferentiate is determined early in the disease.
Horvel et al. compared 29 paired WDL/DDL tumours (21 retro-
peritoneal) by array-based comparative genomic hybridisation. The
analysis segregated all but one pair together, and the genotypic simi-
larities between the components implied that genetic changes preceded
phenotypic progression [41]. This further supports the argument that
the background genotype of some ‘well-differentiated’ liposarcomas
already possess the capacity to dedifferentiate.
12q13-15 amplicon
Although clearly implicated in WDL pathogenesis, MDM2 is de-
scribed as the hallmark of DDL [42]. Creytens et al. performed multi-
plex ligation-dependent probe amplification on 11 retroperitoneal DDL
tumours. They described a significantly higher amplification rate in
DDL compared to WDL of MDM2, HMGA2, YEATS4 and TSPAN31, all
present on 12q13-15 (Fig. 2, Table 1)).
Fig. 2. Pathways active in WD/DDL liposarcoma. MDM2 is overamplified in WDL/DDL and blocks transcription of p53. YEATS4 increases levels of MDM2 by
supression of p21 and p14. CDK4 is commonly found to be co-amplified with MDM2, and phosphorylates Rb, dissociating it from the pRb-E2F complex, allowing E2F
to drive G1/S transition. HMGA2 is amplified in both WDL and DDL and drives CEBP-β mediated expression of PPAR-γ promoting adipogenic differentiation. In DDL
co-amplification of ASK1 and c-JUN blocks CEPB-β driven adipocytic differentiation. The MAPK/ERK pathway is activated in WDL and DDL by FRS2 and FGFR3
amplification respectively. The PI3K pathway is also active; in WDL increased levels of RET drive it, whilst DDR2 amplification in DDL achieves the same. Both
pathways drive cell survival, proliferation and angiogenesis.
Table 1
Evidence summary of genomic drivers of retroperitoneal histological subtypes and related clinical trials.
Histology Genes Associated Pathways Genomic Aberration Targeted Drug Trials
WDL/DDL MDM2 Amplified 20/20 (100%) MDM2 Antagonist RG7112 EudraCT 2009-015522-
10
CDK4 Amplified 20/20 (100%) CDK4/6 Inhibitor - Palbociclib NCT01209598
HMGA2 Amplified and rearranged 38/38 (100%) HMGA2 Inhibitor – Netroposin Not in RPL
FRS2 MAPK/ERK + PI3K/AKT/mTOR Amplified 98/101 (97%) FGFR selective inhibitor NVP-BGJ-398 Not in RPL
DDR2 PI3K/AKT/mTOR Amplified 6/56 (11%), fused in 1 sample Kinase inhibitors – Imatinib/Nilotinib Not in RPL
PPAR-γ Expressed in 44/54 (81.5%) PPARγ ligand – Pioglitazone NCT00004180
YEATS 4 P14/P21/MDM2 Amplified 30/40 (75%) NA NA
DDL FGFR3 PI3K/AKT/mTOR + RAS Amplified in 2/56 (4%) Pan-FGFR Inhibitors Not in RPL
RB Loss of Heterozygosity 16/27 (60%) NA NA
CEBPA 24% methylation Demethylating agent – Decitabine Not in RPL
MLS RET PI3K/AKT/mTOR Overexpressed compared to fat 3/4 (75%) PI3K Inhibitors Not in RPL
FUS-DDIT3 ATM + CEPB-β Gene fusion t(12;16)(q13:p11) in 95% of
cases
Trabectedin - blocks targets of FUS-
DDIT3
NCT00579501
NCT00060944
YAP-1 Hippo/ FUS-DDIT3 Positive 77/85 (90.6%) Verteporfin Not in RPL
PLS P53 Mutated 19/31 (60%) NA NA
VEGF Overexpressed 27/40 (68%) VEGF Inhibitor – Pazopanib/
Regorafenib
NCT01692496
NCT02048371
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In the largest study of its kind Bill et al. correlated the degree of
MDM2 amplification with clinical and biological outcomes. Elevated
MDM2, as measured by genomic amplification and mRNA expression
was associated with a shortened time to recurrence [43]. Other studies
have confirmed a higher MDM2 copy number is associated with poorer
outcomes, poorer response to cytotoxic therapy and interestingly a
higher propensity for a retroperitoneal location [44,45]. There are
limited validated prognostic markers in DDL. As generatingMDM2 copy
number ratios becomes increasingly easy, this should be given serious
consideration as a prognostic biomarker.
As mentioned previously, MDM2 has been targeted in various phase
one and two studies. In a phase 1 study of SAR405838 (a novel MDM2
antagonist), 15/21 patients with DDL had stable disease, but none
displayed an objective response [11]. Importantly, all baseline tumour
biopsies were TP53 wild type. During treatment, Jung et al. with liquid
biopsies demonstrated TP53mutations appearing in circulating cell-free
DNA, with the mutation burden increasing over time and correlating
with a change in tumour size [14]. This was the first clinical demon-
stration of a TP53 mutation in response to an MDM2 antagonist, re-
presenting an escape mechanism for MDM2 amplified cells. A CRISPR
screen in LPS lines exposed to a MDM2 inhibitor to look for synthetic
lethality would be the next step based on these findings, and could have
implications for the future of this class of targeted therapy.
Similar to MDM2, CDK4 plays a pivotal role in DDL. An arrayed loss
of function shRNA screen performed on three DDL cell lines to de-
termine which genes were required for cell proliferation and survival
generated CDK4 as the main hit from the 12q13-15 amplicon [6]. Kim
et al performed co-overexpression of CDK4 and MDM2 in bone marrow
stem cells. Increased cell growth, migration and inhibited adipogenic
differentiating potential was demonstrated when both oncogenes were
overexpressed. In a mouse model, co-overexpression of both genes re-
sulted in a sarcoma with a DDLS-like pathology [46].
It would seem obvious to derive from this data that MDM2 and
CDK4 work synergistically, or at least both are needed to promote tu-
mour proliferation. When DDL cells were exposed to RG7388 (MDM2
antagonist) and palbociclib, together they exerted a greater antitumour
effect than either drug alone. Furthermore, there was an increased PFS
noted in mice [47]. However, recently Sriraman et al. have disputed
this synergistic concept after finding that MDM2 and CDK4 inhibitors
can antagonise each other in their cytotoxicity. They found nutlin
treated liposarcoma cells survived longer when co-treated with palbo-
cicib concluding that CDK4 is required for p53 induced-gene expression
[48].
In the aforementioned Creytens study examining the 12q amplicon,
YEATS4 also came out as having a significantly higher amplification
ratio and was also overexpressed. YEATS4 is a component of the NuA4
histone acetyltransferase (HAT) complex [49]. This complex plays a
potential role in the activation of transcriptional programs associated
with oncogene mediated growth induction and supressing the p53 tu-
mour suppressor pathway. It is also a recognised oncogene in non-small
cell lung cancer. Interestingly, in a large scale genomic-screening study
of DDL cell lines, YEATS4 knockdown was more powerful at reducing
tumour proliferation than loss of MDM2 expression. In the context of
adverse side effects and MDM2 resistance to therapeutic antagonists,
YEATS4 and genes outside of this amplicon should be studied in more
detail, in hope of seeing a translational benefit [50].
Peroxisome proliferator-activated receptor gamma (PPAR-y) is a
nuclear hormone receptor that plays a critical role in the terminal dif-
ferentiation of adipocytes. PPAR-y mRNA has been found in various
liposarcoma subtypes and human liposarcoma cells can be induced to
undergo terminal differentiation by treatment with the PPAR-y ligand
pioglitazone [51]. Despite this, reported results from a phase 2 trial of
rosiglitazone in 12 patients with DDL were disappointing with no
clinical response observed [52].
Features unique to DDL
Co-amplification of 1p32 and 6q23 are mutually exclusive, present
in DDL and never seen in WDL. Genes housed in these regions are
implicated in the dedifferentiation process [38]. 1p32 is home to JUN, a
downstream target of the JNK pathway. ASK1, a protein kinase, is
present on 6q23 and activates the JNK pathway leading to JUN acti-
vation. Snyder et al. defined the role of JUN in 81 liposarcoma samples,
from both the retroperitoneum and extremities, by performing im-
munohistochemistry and FISH on JUN and its activating kinases. JUN
was found to be expressed in the majority of DDL (32/35) and their WD
components, but only in the minority of pure WDL (6/22). They also
noted that when JUN was amplified, it was interspersed with amplified
MDM2, concluding that it was amplified at a similar time in the evo-
lution of these tumours [53].
Mariani et al took this a stage further, analysing the expression le-
vels of key genes in adipogenesis in 16 liposarcomas, of which 14 were
retroperitoneal. By comparing the expression levels through qPCR in
tumours that overexpressed JUN with those that didn’t, – they found
that the C/EBPβ transcriptional network (key to adipogenesis), was
impaired in the group that overexpressed JUN [53]. They concluded
that dedifferentiated tumours are committed to differentiate into adi-
pocytes. Their failure to differentiate was driven by JUN over-
expression, which would be in keeping with the non-adipogenic nature
of DDL. High amplification levels of JUN (>16 copies) have also been
correlated with decreased DFS, corroborating the oncogenic role of JUN
in this disease [44].
Asano et al. examined 104 genes in 37 DDL (29 retroperitoneal.)
Other than the MDM2 and CDK4 genes, the most remarkable category
of amplified genes were those encoding RTKs which were amplified in
11/37 samples. Amplified genes included DDR2, ERBB3, NTRK1,
FGFR3, ROS1 and IGF1R. NTRK1 fusions have recently been succesfully
targeted in other soft tissue sarcomas by larotrectenib – a selective
small-molecule inhibitor of all three TRK proteins – in a tumour ‘ag-
nostic’ fashion [54]. In retroperitoneal DDL, downstream of these RTKs,
point mutations have been documented in the H-Ras gene [55]. The
activation of RTKs and their downstream signalling pathways therefore
provides another avenue for drug targeting and development in DDL.
ZIC-1 is implicated in liposarcoma development. In 51 DDL samples,
when compared with normal fat, ZIC-1 was found to be overexpressed.
When knocked down, there was reduced proliferation, invasion and
higher levels of apoptosis in the DDL lines. The role of the ZIC1 has only
recently been established. It codes for a transcriptional activator in the
differentiation of white and brown fat, and is involved in neuronal
maturation [56]. It is a potential selective therapeutic target due to the
low or absent ZIC1 expression in adult tissues outside of the CNS [57].
One of the best characterised tumour suppressor genes RB1 has been
implicated in liposarcoma. 27 DDL (20 retroperitoneal) underwent
mutational analysis. 60% of DDL showed loss of heterozygosity and
66% expressed an abnormal RB protein. This was compared to 12.5%
and 33% in WDL [58]. A two-hit mechanism was suggested by the
authors as a mechanism to initiate tumour development.
Many sarcomas possess epigenetic faults. Epigenetic mechanisms
modify gene expression without causing any change in cellular DNA.
Taylor et al reported concurrent sequencing of tumour genomes,
exomes and transcriptomes to delineate the molecular landscape of
primary and recurrent retroperitoneal DDL. 24% of DDLS methylomes
R. Tyler, et al. Cancer Treatment Reviews 86 (2020) 102013
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revealed alterations in the differentiation pathway gene CEBPA and
treatment with demethylating agents restored CEBPA expression, was
anti-proliferative and pro-apoptotic in vitro and reduced tumour
growth in vivo [59]. This was the first illustration of a potential role for
demethylating agents in liposarcoma.
Additional genes exclusively amplified in DDL include GLI1,
MAP3K12, CDK2, ALX 1 and TBX5. None of these genes have been
found to be amplified in WDLS [37].
Comparison of genomic aberrations between retroperitoneal and
extremity liposarcoma
It is widely accepted that retroperitoneal WDL/DDL and extremity
ALT/DDL differ clinically in regard to recurrence rates, dedifferentia-
tion and survival. Extremity liposarcomas have a lower local recurrence
rate, dedifferentiate less frequently and have an improved disease
specific survival compared to their retroperitoneal counterparts
[60,61]. The superior outcomes of extremity liposarcoma are likely due
in part to anatomical location, the suitability for radiotherapy and the
fact that clear surgical margins are easier to achieve. What is not un-
derstood is whether underlying genomic differences contribute to this
disparity in outcomes.
There are several reasons why there is a poor understanding of the
genomic differences between the two anatomical subtypes. Firstly, as
with all sarcomas, these are rare tumours and when collected for ana-
lysis tend to be compared on histological subtype, rather than anato-
mical location to increase the power of the datasets. When anatomical
location is analysed, the comparison tends to be made between ‘central
versus peripheral.’ Central can include retroperitoneal, abdominal,
pelvic and mediastinal; which should be treated as separate entities.
Lastly, when comparisons are made, they are done with very low
numbers and rarely validated elsewhere in the literature.
As expected, there is no data comparing primary myxoid and
pleomorphic liposarcomas by anatomical location due to their rarity.
Nevertheless, Italiano et al. compared amplification profiles of
MDM2+/CDK4+ ALT/WDL and DDL with MDM2+/CDK4-ve ALT/
WDL and DDL[17]. Interestingly they found MDM2/CDK4−ve tumours
more frequently occurred in the extremity (71% v 47%, p = 0.0045).
35% of MDM2+ve/CDK4+ve tumours were retroperitoneal, compared
to only 7% of MDM2+ve/CDK4−ve (p = 0.0002). This was further
explored by Bouzid et al. who correlated amplification status with
outcomes in 116 liposarcomas. They found CDK4 amplification to be
associated with an axial location (66% v 39%, p = <0.05) and shorter
recurrence free survival [26].
Riccioti et al. performed a microarray analysis of 47 cases of DDL.
There was a trend towards higher levels of CDK4 amplification
(p = 0.0715) and significantly higher levels of MDM2 amplification
(p = 0.0016) in retroperitoneal DDL compared to other sites. Higher
amplification levels of MDM2 showed a trend towards decreased dis-
ease-free survival [44]. The authors concluded that for a given ampli-
fication of one gene, each additional copy of the other increased the
effect on the disease-free survival. The biological rationale being that
progressive loss of both pathways may have a synergistic effect of cell
cycle dysregulation.
Work comparing genomic drivers of retroperitoneal and extremity
liposarcoma outside of MDM2 and CDK4 is lacking. The authors believe
that differences between the two anatomical subtypes are due in part to
the genomic aberrations that drive them, but there is currently in-
sufficient data to confidently summarise this. Improvements in next
generation sequencing and increased collaboration will bring us a step
closer to answering this question, and potentially narrow the gap in
clinical outcomes.
Myxoid liposarcoma
Myxoid liposarcoma (MLS) accounts for up to 20% of liposarcomas,
predominantly affecting the soft tissues of the extremity. These tumours
can be pure myxoid, classed as a low-grade tumour or contain areas
with greater cellularity, known as round cell dedifferentiation which is
associated with a poorer prognosis [62].
Primary retroperitoneal myxoid liposarcomas are rare. Due to their
rarity in the retroperitoneum, the following summary utilises data
which comes from all anatomical sites. The largest series of myxoid
liposarcomas found only 5 of 213 (2.3%) to arise from the retro-
peritoneum as a primary tumour [45].
FUS-DDIT3
MLS exhibits a paucity of genomic imbalances and in particular
lacks high levels of amplification observed in its retroperitoneal coun-
terparts. They are genetically characterized (>95%) by the presence
of FUS-DDIT3 (t(12;16(q13;p11) fusion gene [63] creating a fusion
transcript, of which three are commonly described. There is no ac-
cepted mechanism for how the FUS-DDIT3 fusion gene drives MLS de-
velopment. However there is strong evidence to support the notion that
this is the primary oncogenic event in these tumours which are other-
wise karyotypically normal [64]. These two genes have been ex-
tensively studied in isolation, and several theories exist as to how their
interaction promotes sarcomagenesis.
Firstly, FUS which is a downstream target of DNA repair regulator
ATM is implicated in DNA damage repair. DDIT3 is able to inhibit
adipocyte differentiation by binding to the CEBP-β family of proteins –
the master adipogenesis regulator. Through this fusion, Conyers et al.
believe that FUS-DDIT3 is able to inhibit adipogenesis whilst main-
taining a population of immature adipocytes in a cycle of proliferation
without differentiation [65].
More recently, Trautman et al. have concentrated on the Hippo
pathway as another mechanism of sarcomagenesis in MLS. Trautman
et al. showed that FUS-DDIT3 expressing mesenchymal stem cells are
dependent on YAP1, a transcriptional co-activator in the Hippo
pathway, linked to tissue growth and tumourigenesis. They used
Verteporfin to inhibit YAP1 which supressed the viability and pro-
liferation of all three MLS cell lines analysed in a dose-dependent
manner [63]. YAP1 represents genuine progress in understanding MLS
development and offers a novel signalling target.
PI3K
The PI3K signalling cascade is implicated in MLS. RET which acti-
vates PI3K is overexpressed in MLS compared to normal fat, and high
expression levels are a poor prognostic feature [66]. PI3K activates the
protein AKT which causes downstream activation, cell cycle entry and
subsequently survival. The catalytic subunit of PI3K – encoded by
PIK3CA was recently shown to have point mutations in 18% of MLS
patients, associated with a shortened disease specific survival and more
likely to be present in round cell tumours than myxoid[50,67]. These
findings are important as a subset of MLS may respond to treatment
with PI3K inhibitors (Fig. 3).
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Trabectedin
MLS differs from other liposarcomas by possessing a relative degree
of chemosensitivity. The most promising drug – trabectedin - works in
multiple ways. It binds to the DNA minor groove dissociating the
aberrant FUS-CHOP transcription factor from promoters of its target
genes and also induces lethal DNA strand breaks [57,68].
It has been shown in a large, phase three multicentre randomised
control trial to improve PFS compared to those treated with dacarba-
zine (PFS 4.2 m vs 1.5 m) [69]. There are however limited treatment
options for trabectedin resistant MLS patients. Bello et al. have sought
to tackle this by working on a patient-derived xenograft with acquired
resistance to trabectedin. The authors hypothesise a defective excision
repair in the resistant tumour is the result of a mutation in a DNA repair
gene UVSSA [70]. UVSSA is likely a DNA repair gene, which could be
prophylactically drugged, in order to overcome resistance.
Pleomorphic liposarcoma
Primary retroperitoneal pleomorphic liposarcoma is very rare and
in keeping with this, molecular studies are limited. The largest review
of PLS documented 32 cases out of 667 liposarcomas (4.8%), and of
these only 4 were retroperitoneal [71]. The published literature agrees
that these tumours have significantly lower recurrence free and overall
survival compared to other liposarcomas, predominantly effect the
extremities and are remarkably chemoresistant.
PLS differs from other LS by containing no consistent cytogenetic
abnormality. Compared to other LS subtypes, PLS has the most chro-
mosomal imbalances with large numbers of gains and deletions.
Conyers et al summarised these as gains in 1p, 1q21-q32, 2q, 3p, 3q,
5p12-p15, 5q, 6p21, 7p, 7q22 with losses of 1q, 2q, 3p, 4q, 10q, 11q,
12p13, 13q14, 13q21-q, 13q23-24 [65]. Ghadimi et al showed over-
expression of VEGF which is housed on one of these gains (6p21.1), and
raises the possibility of VEGF inhibition in PLS.
The largest study of PLS genomics performed microarray analysis
and P53 gene sequencing on 53 samples. P53 was mutated in 60% of
samples, with varying expression levels. P53 mutations are not com-
monly found in other liposarcomas, and are may contribute to che-
moresistance. Retinoblastoma protein (Rb), was found to be even more
poorly expressed, with 77% of samples failing to express it. This was in
concordance with work by Taylor et al.who described a 60% deletion
rate in 24 samples of 13q14.2-q14.3 – a region that houses Rb [6].
It is suggested that the higher frequency of imbalances explains the
aggressive biological nature of the tumour [72]. In terms of ther-
apeutics, it is likely that successful treatment will involve targeting
multiple pathways rather than a single dominant one, reflecting the
complex tumour biology.
Conclusion
Since the advent of next generation sequencing, the number of
studies exploring the molecular landscape of retroperitoneal lipo-
sarcoma has increased, albeit at a slower rate than epithelial counter-
parts. These studies have identified and implicated several targets
outside of the hallmark MDM2/CDK4 in WDL/DDL and FUS-DDIT3 in
MLS. As toxicity and resistance have hampered the progress of MDM2
inhibitors, researchers have looked to other genes inside the 12q13-15
amplicon such as FRS2 in WDL and outside this in DDL with greater
interest in the RTK pathways. A new signalling target of YAP-1 in MLS
represents progress in this morbid cancer, and the outcomes of PI3K
inhibitor trials are eagerly awaited.
Outside of cancer genomics, a slow but steady increase in research
into sarcoma epigenetics and immunology is developing. Stimulation of
host immunity or inhibiting a dysregulated epigenome may provide
breakthroughs in these difficult to treat cancers. New techniques such
as CRISPR, nanopore and single cell sequencing are anticipated to
generate new targets, quickly, and give a much deeper understanding of
the sarcoma genome.
To prevent sarcomas lagging behind epithelial cancers over the next
decade and benefit from these technologies, several crucial steps must
be taken. Greater collaboration between centres is strongly encouraged
to share rare tissue samples and clinical outcome data. In the UK the
results from the 100 K genomes project should be carefully and robustly
explored as this represents a wealth of genomic data where sarcomas
are well represented. Whole geome sequencing of sarcomas should be
introduced as a standard of care where economically feasible, as will be
the case in the authors’ institution in 2021. Those treating sarcomas will
need to closely monitor their evolving biology and therapeutic strate-
gies in this era of personalised medicine, with the ultimate goal of
improving patient outcomes in this complex and morbid disease.
Fig. 3. Pathways active in MLS. As part of the FUS-DDIT3 fusion protein, DDIT3 is able to bind to CEBP-B and prevent adipocytic differentiation. FUS-DDIT3
expressing cells have been shown to be dependent on YAP-1, a transcriptional co-activator. Recurrent promoter mutations in TERT have been documented, and TERT
mutations are associated with telomere lengthening, malignant transformation and progression. The PI3K signalling pathway is highly active in MLS. PIK3CA has
been shown to have point mutations, contributing to the overactivation of the PI3K/AKT pathway.
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